

Preclinical Transplacental Transfer and Pharmacokinetics of Fipronil in Rats[§]

Ya-Ning Chang and Tung-Hu Tsai

Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan (Y.-N.C., T.-H.T.); Graduate Institute of Acupuncture Science, China Medical University, Taichung, Taiwan (T.-H.T.); School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan (T.-H.T.); and Department of Chemical Engineering, National United University, Miaoli, Taiwan (T.-H.T.)

Received April 24, 2020; accepted July 16, 2020

ABSTRACT

Fipronil, a widely used insecticide and pesticide, with its toxic metabolite fipronil sulfone was detected in fipronil-contaminated eggs as a result of inappropriate use. However, little is known about whether fipronil and fipronil sulfone transfer into fetus through the blood-placenta barrier. Our objectives were to investigate the transplacental transfer and the pharmacokinetics of fipronil and fipronil sulfone in rats. Male and female (with 13 days of gestation) Sprague-Dawley rats were used in pharmacokinetics and transplacental transfer experiments, respectively. Biologic samples were collected at each time point after fipronil intravenous or oral administration. To monitor fipronil and fipronil sulfone in the plasma, placenta, amniotic fluid, and fetus, a validated liquid chromatography tandem mass spectrometry method was developed. After fipronil administration in male rats, the oral bioavailability decreased, whereas the biotransformation increased as the dose increased, revealing an enhancement of first-pass effect and a fast metabolism *in vivo*. The results of fipronil transplacental transfer in pregnant rats demonstrated that the concentration of

fipronil and fipronil sulfone varied in the following order, respectively: placenta > plasma > fetus > amniotic fluid and plasma > placenta > fetus > amniotic fluid. This is the first direct evidence that fipronil and fipronil sulfone cross the blood placental barriers and enter the fetus. The amount of fipronil distributed to the fetus was greater than that of fipronil sulfone in the short term, but by contrast, pharmacokinetic data showed that the latter stayed longer in the body. These findings provide constructive information for public health alarm.

SIGNIFICANCE STATEMENT

Fipronil and fipronil sulfone interfere with the GABAergic system. Fipronil can cause thyroid dysfunction, which may affect brain growth and nerve development. Although we knew that fipronil and fipronil sulfone could enter eggs, there was no direct evidence that they would enter fetuses. This research provided evidence on the pharmacokinetics and transplacental transfer of fipronil and fipronil sulfone, confirming our hypothesis.

Introduction

Fipronil, a member of the phenyl-pyrazole chemical family, is commonly used as an insecticide and pesticide to eliminate fleas, lice, and ticks (Tingle et al., 2003). It is a GABA-gated channel and glutamate-gated chloride channel antagonist (Cole et al., 1993; Horoszok et al., 2001). Because of its low resistance potential, high selective toxicity to arthropods (Cole et al., 1993), and long persistence in the environment (Bobé et al., 1998), fipronil occupies approximately 10% of the global pesticide market. Although fipronil is selectively toxic, it still exhibits adverse effects on multiple target organisms and threatens human health. Human exposure may lead to acute poisoning, including

headaches, dizziness, sweating, nausea, vomiting, agitation, and seizures (Mohamed et al., 2004; Lee et al., 2010). The US Environmental Protection Agency also reported that fipronil shows acute toxicity, carcinogenicity, neurotoxicity, endocrine disruption, reproductive toxicity, and developmental toxicity (JMPR, 1997). Fipronil has been classified as a class II moderately hazardous pesticide by the World Health Organization. In addition, fipronil sulfone, the major metabolite of fipronil, is more toxic than fipronil itself in the GABA- and glutamate-activated chloride channel systems (Hainzl et al., 1998; Zhao et al., 2005). Previous pharmacokinetic and metabolism studies have indicated that fipronil primarily converted into fipronil sulfone, which persisted for a much longer time and was stored mainly in adipose tissue and the adrenal glands within the body (Mohamed et al., 2004; Cravedi et al., 2013).

Although there are only a few studies on this subject, fipronil seems to affect the reproduction and development of the fetus. The developmental toxicity studies of fish demonstrated that fipronil exposure in the embryonic stage results in deforming and sublethal effects in Japanese Medaka (Wagner et al., 2017) and impairs the development of spinal

This research was supported in part by research grants from the Ministry of Science and Technology of Taiwan [MOST 107-2113-M-010-005, MOST 109-2113-M-010-007]; the Yin Yen-Liang Foundation Development and Construction Plan of the School of Medicine, National Yang-Ming University [107F-M01]; and the NYMU-FEMH Joint Research Program [108DN31].

<https://doi.org/10.1124/dmd.120.000088>.

[§]This article has supplemental material available at dmd.aspetjournals.org.

ABBREVIATIONS: ABC, ATP-binding cassette; AUC_{last} , area under the plasma concentration–time curve from time zero to the time of the last measurable concentration; AUC_{∞} , area under the plasma concentration–time curve from time zero to infinity; CL, clearance; C_{nom} , nominal concentration; C_{obs} , observed concentration; LC, liquid chromatography; LC-MS/MS, liquid chromatography tandem mass spectrometry; LLOQ, lower limit of quantification; $t_{1/2}$, elimination half-life; T_{max} , time to reach maximum plasma concentration after drug administration.

locomotor pathways in zebrafish (Stehr et al., 2006). For offspring development in rats, prenatal exposure to fipronil affects reflex development, including negative geotaxis reflex delay and early loss of palmar grasp, suggesting interference in the GABAergic system during brain maturation (Udo et al., 2014). In female rats, fipronil interferes with the development of the neonatal female reproductive system, which is evidenced by delay of the vaginal opening and estrus cycle alteration (de Barros et al., 2016). In the reproductive system of male rats, perinatal fipronil exposure changes sperm motility by decreasing motile spermatozoa and increasing nonmobile spermatozoa, indicating that the epididymis may be a target organ of fipronil (de Barros et al., 2017). In addition, fipronil can cause thyroid disruption (Leghait et al., 2009; Herin et al., 2011; Roques et al., 2012), and thyroxine is closely related to brain maturation (Bernal, 2007; Anderson, 2008) and nerve development during fetal growth (Cuevas et al., 2005). Functional disorders caused by thyroxine deficiency, such as vision, motor skills, language, and memory, vary as the gestation progresses (Zoeller and Rovet, 2004).

In 2017, a company blended fipronil, which was prohibited from being used in food-producing animals by either the European Medicines Agency in Europe or the US Environmental Protection Agency, into a proprietary natural cleaning product, DEGA-16. This illegal product was sold to chicken farms, resulting in repeated exposure of poultry to fipronil (Stafford et al., 2018). This fipronil-contaminated egg event was extended to several European and Asian countries, including Taiwan, and caused widespread panic. In a previous study, fipronil sulfone was detected in cord blood, which may be due to chronic fipronil exposure (Kim et al., 2019). However, little is known about the transplacental transfer of fipronil and its pharmacokinetic mechanism, so it is important to determine the possible mechanisms of absorption, distribution, metabolism and excretion for the insecticide fipronil. Our hypothesis is that fipronil and its metabolite fipronil sulfone may penetrate the blood-placental barrier into the fetus. The aim of this study is to develop a valid method using liquid chromatography tandem mass spectrometry (LC-MS/MS) for the analysis of fipronil and fipronil sulfone in the plasma, placenta, amniotic fluid, and fetus to determine the pharmacokinetics, oral bioavailability, and transplacental transfer in rats.

Materials and Methods

Chemicals and Reagents. Fipronil (purity higher than 99% by high performance liquid chromatography [HPLC]) and fipronil sulfone (purity higher than 99% by HPLC) were purchased from Toronto Research Chemicals (Toronto, ON, Canada), and sorafenib (BAY 43-9006; purity higher than 99% by HPLC) was provided by Bayer Pharmaceutical Co., Ltd. (Kaiser-Wilhelm-Allee, Leverkusen, Germany). The acetonitrile from J.T. Baker (Phillipsburg, NJ), methanol from Macron (Hamilton, PA), and triply deionized water from Millipore (Bedford, MA) were used in all experiments. Pentobarbital sodium and heparin sodium were obtained from Sigma-Aldrich (St. Louis, MO).

LC-MS/MS. The LC-MS/MS system consisted of a triple-quadrupole mass spectrometer (LCMS-8030; Shimadzu, Kyoto, Japan) equipped with an electrospray ionization interface coupled to an LC system (LC-20AD XR; Shimadzu). The LC system was equipped with two pumps, a system controller, an autosampler, a column oven, and an online degasser. Chromatographic separation was carried out at 40°C on a Merck Purospher STAR RP-18 endcapped (2.1 × 100 mm, 2 μm) with an isocratic elution of acetonitrile/methanol (6:1, v/v) and water (68:32) at a flow rate of 0.3 ml/min. The temperature of the autosampler was 4°C, and the injection volume was 4 μl. The mass spectrometer was operated in a negative electrospray ionization mode (ESI)- with multiple reaction monitoring scan mode. The interface voltage was 3.5 kV, nebulizing gas (nitrogen) flow was 3.0 l/min, drying gas (nitrogen) flow was 15.0 l/min, dissolution line temperature was 250°C, heat block temperature was 400°C, and collision gas (argon) pressure was 230 kPa.

Method Validation. Fipronil and fipronil sulfone were dissolved in acetonitrile at a concentration of 1 mg/ml each and then mixed together to make a standard solution (500 μg/ml). The standard solution was diluted into several

individual Eppendorf tubes with a paraffin film wrap as a stock solution (10 μg/ml), which was further diluted to give a series of working standard solutions. The internal standard (1 μg/ml) was prepared by diluting sorafenib, which was dissolved in acetonitrile and stored in several individual Eppendorf tubes wrapped with paraffin. All of the solutions were stored at -20°C.

Calibration curves were prepared by adding the working standard solutions into blank male rat plasma to give calibration concentrations of 1, 5, 10, 50, 100, and 500 ng/ml; in blank pregnant rat plasma, amniotic fluid, placenta homogenates, or fetus homogenates, the calibration concentrations were 2.5, 5, 10, 50, 100, and 500 ng/ml. The calibration curve was constructed from the ratio of the peak areas of fipronil or fipronil sulfone and the internal standard to the nominal concentration of fipronil or fipronil sulfone. Linearity was evaluated by the correlation coefficient (r^2), and a value of at least 0.995 was considered to be acceptable.

Six replications of the calibration curve were performed on the same day (intraday) and over six consecutive days (interday) to evaluate the precision and accuracy. Accuracy describes the closeness of the mean results [observed concentration (C_{obs})] of this method to the true concentration [nominal concentration (C_{nom})]. Accuracy, quantified as relative error (RE), was calculated as $\text{RE} (\%) = [(C_{\text{obs}} - C_{\text{nom}})/C_{\text{nom}}] \times 100\%$. Precision is the proximity of each individual result to the others. Precision, quantified as the correlation of variation (CV), was calculated as follows: $\text{CV} (\%) = [S.D./C_{\text{obs}}] \times 100\%$. The relative error and coefficient of variation were maintained within $\pm 15\%$, except for the lower limit of quantification (LLOQ), which was not permitted to exceed $\pm 20\%$.

The matrix effects and recovery were calculated by three sets of samples. Fipronil and fipronil sulfone were evaluated at 1, 50, and 500 ng/ml in male samples and 2.5, 50, and 500 ng/ml in female samples, and sorafenib was evaluated at 50 ng/ml. For set 1, working solutions of fipronil, fipronil sulfone, and internal standard were diluted with acetonitrile. For set 2, blank plasma or tissue homogenate was processed as described under sample preparation without the drug to obtain blank matrix, followed by the addition of the working solution and internal standard, giving postextraction spiked fipronil and fipronil sulfone samples. For set 3, working solution and blank plasma or tissue homogenate were mixed and subjected to sample preparation, obtaining pre-extraction spiked fipronil and fipronil sulfone samples. Then, all samples were injected into the LC-MS/MS system for analysis.

The matrix effect was determined by comparing the peak area ratio of the postextraction spiked samples (set 2) to that of the standard solution samples (set 1). The recovery was quantified as the peak area ratio of the pre-extraction spiked samples (set 3) to that of the postextraction spiked samples (set 2).

Experimental Animals and Drug Administration. The animal experimental protocol listed below was reviewed and approved by the institutional animal care and use committee (approval number 1070525) by the Institutional Animal Experimentation Committee of the National Yang-Ming University and was consistent with the guidelines of the National Research Council. Male Sprague-Dawley rats (230 ± 20 g) and female Sprague-Dawley rats (350 ± 30 g) with 13 days of gestation were used in the bioavailability and transplacental transfer experiments, respectively, and were purchased from the National Yang-Ming University Animal Center, Taipei, Taiwan. Laboratory rodent diet 5001 (PMI Feeds, Richmond, IN) was used as food. Rats were housed with a 12-hour light/dark photoperiod cycle and given ad libitum access to water.

Rats were anesthetized with pentobarbital sodium (50 mg/kg, i.p.). A polyethylene tubing filled with heparinized saline (100 U/ml) was inserted into the right jugular vein emerging from the back of the neck and guided through a protective cap for fixation. After surgery, the rats were allowed to rest and recover in a clean cage overnight before drug administration. After the stabilization period, fipronil was administered (1 mg/kg, i.v.; 3, 10, or 30 mg/kg, oral) to the rats ($n = 6$ for each group). Collection of the blood samples was divided into two sets of time points. One set was 5, 15, 30, 45, 60, 90, 120, 150, 180, 240, and 360 minutes after intravenous administration of fipronil, and the other was 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, and 24 hours after oral administration of fipronil. At each time point, 200 μl of blood was drawn into heparin-rinsed Eppendorf tubes and then centrifuged at 13,000 rpm for 10 minutes at 4°C to obtain plasma. Plasma was stored at -20°C until analysis.

Pregnant rats were anesthetized with pentobarbital sodium (50 mg/kg, i.p.) and remained anesthetized as needed throughout the experimental period. The left

femoral vein was catheterized with polyethylene tubing for drug administration. The laparotomy incision was covered using gauze immersed in warm saline. To investigate the transplacental transfer of fipronil and fipronil sulfone, fipronil was administered intravenously via the femoral vein by bolus injection at a dose of 10 mg/kg ($n = 6$). Biologic samples, including maternal blood, placenta, amniotic fluid, and fetus from one single uterus of a dam, were collected at each time point at 15, 30, 60, 120, 180, 240, 300, and 360 minutes after drug administration. Collected placenta and fetus samples were weighed immediately, and all samples were stored at -20°C until further sample preparation.

Sample Preparation. The placenta or fetus was homogenized with a 2-fold amount of 0.9% normal saline (w/v) using a Polytron PT 2100 homogenizer (Kinematica, Lucerne, Switzerland). The homogenate was centrifuged at 13,000 rpm for 5 minutes at 4°C . The supernatant was collected and stored at -20°C . Biologic samples (50 μl) were mixed with 10 μl of internal standard (sorafenib 1 $\mu\text{g}/\text{ml}$ in acetonitrile) and 140 μl of acetonitrile for protein precipitation. The mixture was vortexed for 5 minutes and then centrifuged at 13,000 rpm for 10 minutes at 4°C . The supernatant was filtered through a 0.22- μm filter. An aliquot (4 μl) of the filtrate was analyzed using LC-MS/MS.

Pharmacokinetic Parameters Analysis and Statistics. Pharmacokinetic parameters were calculated using WinNonlin Standard Edition version 5.3 (Pharsight Corp., Mountain View, CA) with an intravenous bolus input and an extravascular input noncompartmental model for the intravenous and oral groups, respectively. In addition, an intravenous bolus input noncompartmental model was employed to obtain the pharmacokinetic parameters for the transplacental transfer experiment. All data are presented as means \pm S.D.. ANOVA was used to evaluate differences using IBM SPSS Statistics 24.0 (IBM Corp., Armonk, NY), and a value of $P < 0.05$ was taken as statistically significant.

Results

Optimization of LC-MS/MS. An LC-MS/MS method was developed to determine the fipronil, fipronil sulfone, and internal standard analytes. By optimizing the different collision energies, there was good sensitivity at m/z 434.95 \rightarrow 329.95 for fipronil with a collision energy of 18 V, m/z 450.95 \rightarrow 414.95 for fipronil sulfone with a collision energy of 16 V, and m/z 463.10 \rightarrow 194.10 for the internal standard with a collision energy of 15 V (Supplemental Fig. 1). After modifying the LC conditions, the experimental results revealed that the sharpest peaks and best retention times occurred when a reversed-phase C18 minibore column was used to separate the analytes from the biologic matrix with an isocratic elution system consisting of acetonitrile/methanol (6:1, v/v) and water (68:32, v/v). Under these conditions, the retention times of fipronil, fipronil sulfone, and sorafenib were 3.2, 4.2, and 2.9 minutes, respectively (Supplemental Fig. 2).

The typical LC-MS/MS chromatograms of the blank biologic samples, including male rat plasma, pregnant rat plasma, placenta, amniotic fluid, and fetus, presented no obvious endogenous interference within analyte-free samples (Supplemental Fig. 2, A1, B1, C1, and D1). As for the chromatograms of blank plasma or organ homogenates spiked with fipronil, fipronil sulfone, and an internal standard, and those depicting samples collected after fipronil administration, the determination of fipronil and fipronil sulfone in biologic samples illustrated acceptable selectivity (Supplemental Fig. 2, A2–6, B2–3, C2–3, and D2–3).

Calibration Curves and Linearity. Linearity was achieved for the calibration curves, which were derived from the peak area ratios of fipronil and the internal standard. The linear range for the calibration curves in male rat plasma was 1–500 ng/ml, and it was 2.5–500 ng/ml in pregnant rat plasma, placenta, amniotic fluid, and fetus homogenate. The correlation coefficient of all calibration curves was greater than 0.995. The LLOQ for the male samples was 1 ng/ml, and the LLOQ for the female samples was 2.5 ng/ml.

Matrix Effect and Recovery Evaluation. Matrix effects and recoveries were used to assess ion suppression or enhancement and loss in sample preparation. By using the postextraction fortification method, the average matrix effects of fipronil in both male and pregnant rat plasma, placenta, amniotic fluid, and fetus samples were $94.55\% \pm 7.23\%$, $98.71\% \pm 5.42\%$, $98.73\% \pm 6.32\%$, $90.96\% \pm 2.28\%$, and $99.61\% \pm 3.49\%$, respectively. Additionally, the average matrix effects of fipronil sulfone in both male and pregnant rat plasma, placenta, amniotic fluid, and fetus samples were $92.12\% \pm 7.54\%$, $96.93\% \pm 4.49\%$, $96.20\% \pm 2.02\%$, $84.94\% \pm 1.73\%$, and $93.01\% \pm 3.06\%$, respectively. Comparing the pre-extraction and postextraction spiked solutions, the mean extraction recoveries of fipronil in both male and pregnant rat plasma, placenta, amniotic fluid, and fetus samples were $98.57\% \pm 9.23\%$, $95.03\% \pm 2.90\%$, $97.95\% \pm 4.72\%$, $96.47\% \pm 1.75\%$, and $101.2\% \pm 2.36\%$, respectively. The average recoveries of fipronil sulfone in both male and pregnant rat plasma, placenta, amniotic fluid, and fetus samples were $99.03\% \pm 11.83\%$, $103.0\% \pm 2.24\%$, $99.47\% \pm 2.46\%$, $102.2\% \pm 4.27\%$, and $105.8\% \pm 1.87\%$, respectively (Supplemental Table 1).

The results above demonstrated that the amniotic fluid samples had the most severe ion suppression in the analysis of fipronil and fipronil sulfone. However, all the matrix effects and extraction recoveries of the samples were less than $\pm 20\%$, meaning that the sample preparation had no significant effect on fipronil, fipronil sulfone, or the internal standard in the biologic samples.

Intraday and Interday Precision and Accuracy. In intraday assays, the precision ranged from 0.49% to 9.24%, and the accuracy ranged from -10.81% to 15.11% for fipronil analysis (Supplemental Table 2). The precision ranged from 0.66% to 9.62%, and the accuracy ranged from -7.24% to 8.31% for fipronil sulfone analysis (Supplemental Table 3). In interday assays, the precision was in the range of 0.46%–10.51%, and the accuracy was in the range of -4.11% through 15.44% for fipronil analysis (Supplemental Table 2). The precision was in the range of 0.96%–15.98%, and the accuracy was in the range of -12.92% through 18.76% for fipronil sulfone analysis (Supplemental Table 3).

The precision and accuracy values were within $\pm 15\%$, and the LLOQ values were less than $\pm 20\%$, which was considered to be in the acceptable experimental concentration range. This result indicated that the method was considered acceptable and reproducible.

Pharmacokinetics of Fipronil and Fipronil Sulfone. The pharmacokinetics of fipronil and fipronil sulfone were assessed after intravenous administration 1 mg/kg of fipronil and oral administration at low, medium, and high doses of fipronil (3, 10, and 30 mg/kg). The maximum plasma concentrations (C_{max}) of fipronil for the three oral doses from low to high were 8.81 ± 1.91 , 23.76 ± 9.21 , and 47.62 ± 20.16 ng/ml, respectively, and the area under the plasma concentration–time curve from time zero to the time of the last measurable concentration (AUC_{last}) of fipronil for the doses from 3 to 30 mg/kg were 72.26 ± 16.80 , 172.4 ± 48.02 , and 454.3 ± 186.2 h ng/ml, respectively. The C_{max} values of fipronil sulfone for the doses of 3, 10, and 30 mg/kg were 18.74 ± 11.56 , 56.92 ± 18.28 , and 152.5 ± 35.62 ng/ml, respectively; and the AUC_{last} values of fipronil sulfone for the low, medium, and high doses were 286.7 ± 146.4 , 1052 ± 414.1 , and 3005 ± 671.6 h ng/ml, respectively. The pharmacokinetic data demonstrated that the C_{max} and AUC were proportional to the administered oral dose of fipronil and fipronil sulfone and had a significant difference ($P < 0.001$) (Table 1).

By comparing intravenous administration and oral administration of fipronil using the formula oral bioavailability ($F; \%$) = $(\text{AUC}_{\text{oral}} / \text{dose}_{\text{oral}}) / (\text{AUC}_{\text{iv}} / \text{dose}_{\text{iv}}) \times 100\%$, the results were $19.28 \pm 4.48\%$, $13.80 \pm$

TABLE 1
Pharmacokinetic data from plasma for (A) fipronil and (B) fipronil sulfone in male rats

Data are expressed as means \pm S.D. (n = 6).

Pharmacokinetic Parameter	Fipronil (1 mg/kg, i.v.)	Fipronil (3 mg/kg, Oral)	Fipronil (10 mg/kg, Oral)	Fipronil (30 mg/kg, Oral)	P Value
Fipronil					
$t_{1/2}$ (h)	2.66 \pm 0.56	12.16 \pm 5.21	9.16 \pm 11.28	4.44 \pm 1.19	0.207
T_{max} (h)	0.83 \pm 0.00	1.75 \pm 0.88	2.17 \pm 0.75	3.17 \pm 1.47	0.098
C_{max} (ng/ml)	100.5 \pm 39.65	8.81 \pm 1.91 ^a	23.76 \pm 9.21 ^b	47.62 \pm 20.16	<0.001*
AUC _{last} (h ng/ml)	125.0 \pm 20.66	72.26 \pm 16.80 ^a	172.4 \pm 48.02 ^b	454.3 \pm 186.2	<0.001*
AUC _∞ (h ng/ml)	153.8 \pm 17.90	119.4 \pm 16.19 ^a	204.6 \pm 42.84 ^b	481.3 \pm 197.1	<0.001*
CL/F (l/h per kilogram)	6.58 \pm 0.82	25.50 \pm 3.46 ^{a,c}	50.84 \pm 11.29	70.36 \pm 24.28	0.001*
MRT _∞ (h)	3.34 \pm 0.88	17.32 \pm 6.63	12.98 \pm 11.94	8.30 \pm 1.39	0.177
Bioavailability (%)		19.28 \pm 4.48 ^a	13.80 \pm 3.84	12.12 \pm 4.97	0.035*
Fipronil sulfone					
T_{max} (h)	1.75 \pm 0.42	4.00 \pm 1.10 ^a	6.33 \pm 3.20 ^b	14.00 \pm 2.19	<0.001*
C_{max} (ng/ml)	27.66 \pm 6.65	18.74 \pm 11.56 ^{a,c}	56.92 \pm 18.28 ^b	152.5 \pm 35.62	<0.001*
AUC _{last} (h ng/ml)	130.35 \pm 25.92	286.7 \pm 146.4 ^{a,c}	1052 \pm 414.1 ^b	3005 \pm 671.6	<0.001*
Biotransformation (%)	104.8 \pm 14.88	400.8 \pm 197.4	608.4 \pm 197.8	730.4 \pm 257.7	0.058

MRT_∞, mean residence time from time zero to infinity.

* P < 0.05 compared with the 3, 10, and 30 mg/kg, oral, fipronil groups.

^a P < 0.05 compared with the 3 and 30 mg/kg, oral, fipronil group.

^b P < 0.05 compared with the 10 and 30 mg/kg, oral, fipronil group.

^c P < 0.05 compared with the 3 and 10 mg/kg, oral, fipronil group.

3.84% and 12.12 \pm 4.97% for the 3, 10 and 30 mg/kg doses of fipronil, respectively, and there was a significant dose-dependent decrease ($P=0.035$). The low oral bioavailability should be due to the first-pass effect. The biotransformation ratio ($AUC_{\text{fipronil sulfone}} / AUC_{\text{fipronil}}$) \times 100% was 104.8 \pm 14.88% for fipronil intravenous administration (1 mg/kg) However, the biotransformation ratios for oral administration were 400.8% \pm 197.4%, 608.4% \pm 197.8%, and 730.4% \pm 257.7% after fipronil administration (3, 10, and 30 mg/kg, oral), respectively (Table 1). The biotransformation ratio for oral administration was more than 4-fold greater than that of the intravenous administration. These results indicated that fipronil metabolism was closely related to the hepatobiliary system and the gastrointestinal tract.

The clearance (CL/F) of fipronil for the three orally administered doses were 25.50 \pm 3.46, 50.84 \pm 11.29, and 70.36 \pm 24.28 l/h per kilogram, respectively, which significantly increased from low to high doses of oral administration ($P = 0.001$) (Table 1). Combining the CL/F and the biotransformation results with the pharmacokinetic data of the elimination half-life ($t_{1/2}$) and the mean residence time from time zero to infinity, which both decreased according to the dose, revealed that fipronil was metabolized vary rapidly to the metabolite fipronil sulfone in vivo and that the transforming speed was elevated by the dose. Moreover, the time to reach the maximum plasma concentration after drug administration (T_{max}) of fipronil sulfone was 4.00 \pm 1.10, 6.33 \pm 3.20, and 14.00 \pm 2.19 hours by the oral administration of 3, 10, and 30 mg/kg of fipronil, respectively, which increased significantly by the dose ($P < 0.001$) (Table 1). The $t_{1/2}$ of fipronil sulfone increased up to the plateau concentration (Fig. 1). Both pharmacokinetic parameters suggested that the elimination of fipronil sulfone might be slow.

Transplacental Transfer of Fipronil and Fipronil Sulfone. This validated LC-MS/MS method was used to determine the biodistribution of fipronil and fipronil sulfone in the plasma, placenta, amniotic fluid, and fetus after fipronil administration (10 mg/kg, i.v.) in pregnant rats. The concentration of fipronil gradually decreased after fipronil administration (10 mg/kg, i.v.). Then, the concentration of fipronil sulfone gradually increased to reach an average C_{max} of 60.52 ng/ml at the T_{max} of 4.17 hours in the pregnant rat plasma. A similar phenomenon occurred in the placenta, amniotic fluid, and fetus, for which the T_{max} of fipronil sulfone was approximately 4 hours. In addition, the T_{max} of fipronil in the placenta, amniotic fluid, and fetus were all approximately

2 hours. These results suggest that the biodistributions of fipronil and fipronil sulfone for placental transfer were approximately 2 and 4 hours, respectively (Fig. 2; Table 2).

For fipronil, the C_{max} and the AUC_{last} in the plasma and placenta were both significantly higher than that of amniotic fluid and fetus, respectively ($P < 0.001$). The AUC_∞ of the placenta also significantly exceeded the AUC_∞ of the amniotic fluid and fetus ($P < 0.001$). In terms of fipronil sulfone, the C_{max} and the AUC_{last} in the plasma were significantly higher than that of amniotic fluid and fetus ($P < 0.001$). The C_{max} of the placenta was significantly higher than the C_{max} of the amniotic fluid ($P = 0.001$) (Table 2).

The AUC_{last} values of fipronil in the pregnant rat plasma and placenta were 2859 \pm 1438 and 3411 \pm 1097 h ng/ml, respectively. The AUC_{last} values of fipronil sulfone in the pregnant rat plasma and placenta were 287.7 \pm 162.2 and 215.5 \pm 87.45 h ng/ml, respectively (Table 2). Comparing the AUC_{last} of the plasma to the placenta for both fipronil and fipronil sulfone, it can be found that the AUC_{last} of fipronil was lower in the plasma than in the placenta, whereas the AUC_{last} of fipronil sulfone was higher in the plasma than in the placenta.

The ratio of $AUC_{\text{fetus}}/AUC_{\text{plasma}}$ was defined as the mother-to-fetus pass transformation ratio of the analyte. The AUC_{last} values of the fetus in fipronil and fipronil sulfone were 1085 \pm 268.8 and 84.06 \pm 23.83 h ng/ml, respectively (Table 2). The average ratio of $AUC_{\text{fetus}}/AUC_{\text{plasma}}$ for fipronil was approximately 38%, whereas this ratio was approximately 29% for fipronil sulfone, suggesting that both fipronil and fipronil sulfone partially penetrated the blood-placental barrier to reach the fetus.

Discussion

The pharmacokinetic data in our study demonstrated that the C_{max} and AUC of both fipronil and fipronil sulfone are proportional to the administered oral dose of fipronil, suggesting a linear pharmacokinetic phenomenon. A previous study mentioned that the first-pass effect of hepatic metabolism in the oral route was very important for fipronil (Roques et al., 2012), which is consistent with our findings. First, the oral bioavailability is only 12%–19%. Second, the oral biotransformation is about four to seven times higher than the intravenous one. These pharmacokinetic phenomena demonstrate that compared with intravenous administration, the concentration of fipronil dramatically falls




Fig. 1. Concentration-time curves of (A) fipronil and (B) fipronil sulfone in male rat plasma after fipronil administration at the doses of 1 mg/kg, i.v. (●); 3 mg/kg, per os (p.o.) (○); 10 mg/kg, p.o. (▼), and 30 mg/kg, p.o. (△). Data are expressed as means \pm S.D. ($n = 6$).

in the systemic circulation after oral administration, whereas the concentration of fipronil sulfone greatly rises. In addition, the average bioavailability of doses 3, 10, and 30 mg/kg is about 19.28%, 13.80%, and 12.12%, respectively, and the average bio-transformation is about 400.8%, 608.4%, and 730.4%, respectively (Table 1). As the dose increases, the trends of both the above are reverse but similar in magnification, reflecting the possibility of a first-pass effect enhancement. Fipronil is metabolized through three major mechanisms (Caboni et al., 2003). The first step is the oxidation step, which leads to fipronil sulfone formation via cytochrome P450 (Scharf et al., 2000). In humans, CYP3A4 is the major isoform of cytochrome P450 that metabolizes fipronil, and its activity toward fipronil is five times higher than that of CYP2C19 (Tang et al., 2004). The second step is the reduction step, which produces fipronil sulfide. The third step is the hydrolysis step, which forms fipronil amide. Considering the interspecies differences,




Fig. 2. Concentration-time curves of (A) fipronil and (B) fipronil sulfone in pregnant rat plasma (●), placenta (○), amniotic fluid (▼), and fetus (△) after 10 mg/kg fipronil intravenous administration. Data are expressed as means \pm S.D. ($n = 6$).

although the main metabolite of fipronil is fipronil sulfone in both humans and rats, and the Michaelis constant (K_m) values of the liver microsomes are similar, there is a 3.8-fold-higher rate of fipronil sulfone formation in rat liver microsomes than in human liver microsomes (Tang et al., 2004).

In a previous pharmacokinetic study of rats, after administration of fipronil and fipronil sulfone separately via intravenous and oral administration, the results indicated that fipronil sulfone was substantially converted from fipronil and lasted longer than fipronil (Roques et al., 2012). Compared with the previous study, a dose-dependent (3, 10, and 30 mg/kg) study design is applied in the current study and obtained consistent results. In addition, from the biotransformation and the half-life of fipronil sulfone reaching the plateau concentration, it is confirmed that fipronil is rapidly metabolized in the organisms and the elimination process of fipronil sulfone may be slow. The half-lives of fipronil in this study at 3 and 30 mg/kg were 12.16 and 4.44 hours, respectively. A previous report used radiolabeling to detect and measure the elimination half-lives of fipronil at 4 and 40 mg/kg in Charles River CD rats. The

TABLE 2

Pharmacokinetic data for the plasma, placenta, amniotic fluid, and fetus of fipronil (10 mg/kg, i.v.) in pregnant rats

Data are expressed as means \pm S.D. (n = 6).

Pharmacokinetic Parameter	Plasma	Placenta	Amniotic Fluid	Fetus	P Value
Fipronil					
T _{max} (h)	0.25 \pm 0.00	2.25 \pm 1.60	2.00 \pm 1.26	2.29 \pm 2.52	0.125
C _{max} (ng/ml)	1060 \pm 443.3 ^{a,b}	820.1 \pm 282.6 ^{c,d}	182.7 \pm 57.79	286.4 \pm 92.49	<0.001*
AUC _{last} (h ng/ml)	2859 \pm 1438 ^{a,b}	3411 \pm 1097 ^{c,d}	787.4 \pm 242.9	1085 \pm 268.8	<0.001*
AUC _∞ (h μ g/ml)	4468 \pm 1933	6642 \pm 3319 ^{c,d}	1253 \pm 386.0	2204 \pm 1006	0.002*
Fipronil sulfone					
T _{max} (h)	4.17 \pm 1.60	4.16 \pm 1.69	4.83 \pm 0.23	4.83 \pm 1.17	0.619
C _{max} (ng/ml)	60.52 \pm 32.24 ^{a,b}	52.80 \pm 17.78 ^c	8.84 \pm 3.97	22.43 \pm 5.79	<0.001*
AUC _{last} (h ng/ml)	287.7 \pm 162.2 ^{a,b}	215.5 \pm 87.45	54.72 \pm 39.96	84.06 \pm 23.83	0.001*

^aP < 0.05 compared with the plasma and amniotic fluid group.^bP < 0.05 compared with the plasma and fetus group.^cP < 0.05 compared with the placenta and amniotic fluid group.^dP < 0.05 compared with the placenta and fetus groups. *P < 0.05 compared among the plasma, placenta, amniotic fluid and fetus groups.

former obtained 183 hours in males and 245 hours in females; the latter got 135 hours in males and 171 hours in females (JMPR, 1997). The report also proposed that a long half-life reflected the slow release from compartments such as fat, which explained the change in the blood concentration of fipronil sulfone in our study (JMPR, 1997). However, our findings may be inconsistent with previous reports. A potential explanation is that the previous report used radiolabels for the detection of fipronil in the analyte, which might not be sensitive enough to distinguish between fipronil and its metabolites. In contrast to our experiment, the fipronil and the metabolite fipronil sulfone were separated by the chromatographic column and detected by tandem mass spectrometer individually. Another explanation for the different pharmacokinetic results could be due to the dissimilar strains, ages, and weights of the experimental animals.

The distribution study for fipronil supports the above discourse. The highest levels of fipronil residue were found in abdominal fat, followed by the adrenals. The intermediate levels were observed in the liver, pancreas, thyroid, and ovaries, and the lowest levels were in the muscle, brain, heart, and cardiac blood (JMPR, 1997). Excretion research can also provide some explanation for these phenomena. Feces not only appears to be the main route of excretion, but fipronil itself can also be detected from it, whereas it is not found in any other excrement (JMPR, 1997; Cravedi et al., 2013). In urine, the secondary route of excretion, there are several metabolites found, including detrifluoromethylsulphanyl fipronil and its derivative (Cravedi et al., 2013).

Among most of the literature on organ distribution of fipronil, the placenta, amniotic fluid, and fetus distribution has not been mentioned. Our research provided important information that in decreasing order, the fipronil concentration is from the placenta, plasma, fetus to amniotic fluid, but the fipronil sulfone concentration is from the plasma, placenta, fetus to amniotic fluid after fipronil administration in the pregnant rat. This result was supported by previous research showing that fipronil sulfone was detected in the serum of mother-neonate pairs (Kim et al., 2019). At the same time, we put forward a different view that long-term exposure to fipronil may not lead to detection of the parent compound in the fetus, which is related to the half-life of fipronil itself (Tang et al., 2004), but in a short period of time, fipronil can still enter the fetus. Considering the developmental and reproductive toxicity of fipronil (JMPR, 1997; Udo et al., 2014; de Barros et al., 2016, 2017), it is still a potential menace. In addition, the concentration distribution could be explained by the scheme of an in vivo animal model for the transplacental transfer of oseltamivir and oseltamivir carboxylic acid in our previous study (Lin et al., 2012). Fipronil and fipronil sulfone penetrate the placenta from the maternal blood through the blood-placental barrier,

enter the fetus, and finally, spread to the amniotic fluid, thus causing a sequential decrease in drug concentration.

Regarding the inconsistency in concentration distribution order of fipronil and fipronil sulfone, the affinity of the drugs and placental tissue may have a certain effect. Some drugs have been found to bind to and accumulate in placental tissue ex vivo, causing a depot phenomenon (Ala-Kokko et al., 2000). This might be due to the uptake of the lipophilic drug by the syncytiotrophoblast in the placenta (Sastry, 1999). If the drug has a high affinity for placental tissue, it cannot be easily released from the placenta into fetal circulation, especially for lipophilic drugs. In our research, the higher concentration of fipronil found in the placenta compared with maternal plasma may have been affected by this phenomenon.

Various reasons contributed to the mother-to-fetus transfer ratio of fipronil and fipronil sulfone being 38% and 29%, respectively, which indicates an incomplete transfer (Griffiths and Campbell, 2014). This can be explained by the physicochemical properties and the mechanism of the drug, which passively diffuses through the blood-placental barrier (Syme et al., 2004; Griffiths and Campbell, 2014). The molecular mass of fipronil and fipronil sulfone is less than 500 Da for each, and both are lipophilic, causing a higher opportunity to cross the blood-placental barrier. However, lipophilic drugs with a good protein binding rate usually have more difficulty entering the fetus. According to a previous report, fipronil binds to fatty acid site 1 of human serum albumin in humans (Ascenzi et al., 2018). Moreover, the ATP-binding cassette (ABC) transporters of P-glycoprotein and breast cancer resistance protein are abundantly expressed in the syncytiotrophoblast layers of placenta and in the fetal brain, liver, spleen, and intestine throughout gestation to protect the fetus from drugs in the maternal circulation (Han et al., 2018). In the fipronil-resistant strain of *Plutella xylostella* larvae, *ABCG2* gene is upregulated, but *ABCB1* gene is downregulated (Qi et al., 2016). It seems that P-glycoprotein/ABCB1 and breast cancer resistance protein/ABCG2 could impact fipronil transportation into placenta and fetus. Our data suggest that both fipronil and fipronil sulfone partially penetrate into placenta, amniotic fluid, and fetus (Table 2).

On the other hand, the discrepancy in the mother-to-fetus transfer ratio between fipronil and fipronil sulfone is a complicated issue. The main metabolic enzymes of fipronil in humans are described as follows: CYP3A4 exists in the fetal liver after 9 weeks of gestation and in the placenta, whereas CYP2C19 presents in the fetal liver after 12 weeks but not in the placenta (Hakkola et al., 1996, 1998; Hines, 2008). However, the fetoplacental metabolism has little contribution to the overall pharmacokinetics of drugs because of the small organ sizes and low

cytochrome P450 content of the fetus and placenta. Similarly, studies on the above two enzymes in rat fetus and placenta are also inadequate. It is speculated that the fipronil sulfone in the fetus is mostly transmitted by the maternal blood, thus showing that the lipophilic properties of drugs are the main factors contributing to this inequality. Drugs with high lipophilicity are more likely to cross the blood-placental barrier (Dickinson et al., 1989). The octanol-water partition value of fipronil (4.0) is greater than the octanol-water partition value of fipronil sulfone (3.8), inducing a lower mother-to-fetus transfer ratio for fipronil sulfone (European Food Safety Authority (EFSA), 2006).

There have been many studies on the transplacental transfer of insecticides and pesticides. In animals, ivermectin can be detected in fetal blood after maternal or fetal intravenous administration to sheep (Pérez et al., 2008). Through collected carcasses, polychlorinated biphenyls, polybrominated diphenyl ethers, and organochlorine pesticides can be found in the blubber of ringed seal fetuses (Brown et al., 2016). Additionally, pyrethroid insecticides and persistent organic pollutants in dolphin fetal tissue have also been reported (Alonso et al., 2015; Barbosa et al., 2018). In humans, such studies are most common in analytical epidemiology, and most studies are about organochlorine pesticides, which can be found in cord blood (Sala et al., 2001; Ma et al., 2014; Zhang et al., 2018). Although fipronil is not an organochlorine pesticide, according to our study, it can still be transferred through the placenta to the fetus.

In conclusion, we have successfully developed a validated LC-MS/MS method to monitor analytes in various organs and applied this method to assess the pharmacokinetics and transplacental transfer of fipronil and fipronil sulfone. The pharmacokinetic study revealed that after oral fipronil administration, the persistent toxicity of metabolite fipronil sulfone is accelerated by biotransformation in a dose-dependent manner as the dose increases. Additionally, since both fipronil and fipronil sulfone incompletely transfer through the blood-placental barrier to the fetus, this preclinical study provides conclusive information to suggest that pregnant women should avoid exposure to fipronil under any circumstances.

Authorship Contributions

Participated in research design: Tsai.

Conducted experiments: Chang.

Performed data analysis: Chang.

Wrote or contributed to the writing of the manuscript: Chang, Tsai.

References

Ala-Kokko T, Myllynen P, and Vähäkangas K (2000) Ex vivo perfusion of the human placental cotyledon: implications for anesthetic pharmacology. *Int J Obstet Anesth* 9:26–38.

Alonso MB, Feo ML, Corcellas C, Gago-Ferrero P, Bertozzi CP, Marigo J, Flach L, Meirelles AC, Carvalho VL, Azevedo AF, et al. (2015) Toxic heritage: maternal transfer of pyrethroid insecticides and sunscreen agents in dolphins from Brazil. *Environ Pollut* 207:391–402.

Anderson GW (2008) Thyroid hormone and cerebellar development. *Cerebellum* 7:60–74.

Ascenzi P, Leboffe L, Toti D, Polticelli F, and Trezza V (2018) Fipronil recognition by the FA1 site of human serum albumin. *J Mol Recognit* 31:e2713.

Barbosa APM, Méndez-Fernández P, Dias PS, Santos MCO, Taniguchi S, and Montone RC (2018) Transplacental transfer of persistent organic pollutants in La Plata dolphins (Pontoporia blainvillei; Cetartiodactyla, Pontoporiidae). *Sci Total Environ* 631–632:239–245.

Bernal J (2007) Thyroid hormone receptors in brain development and function. *Nat Clin Pract Endocrinol Metab* 3:249–259.

Bobé A, Meallier P, Cooper J-F, and Coste CM (1998) Kinetics and mechanisms of abiotic degradation of fipronil (hydrolysis and photolysis). *J Agric Food Chem* 46:2834–2839.

Brown TM, Ross PS, and Reimer KJ (2016) Transplacental transfer of polychlorinated biphenyls, polybrominated diphenylethers, and organochlorine pesticides in ringed seals (Pusa hispida). *Arch Environ Contam Toxicol* 70:20–27.

Caboni P, Sammelson RE, and Casida JE (2003) Phenylpyrazole insecticide photochemistry, metabolism, and GABAergic action: ethiprole compared with fipronil. *J Agric Food Chem* 51:7055–7061.

Cole LM, Nicholson RA, and Casida JE (1993) Action of phenylpyrazole insecticides at the GABA-gated chloride channel. *Pestic Biochem Physiol* 46:47–54.

Cravedi JP, Delous G, Zalko D, Vigié C, and Debrauer L (2013) Disposition of fipronil in rats. *Chemosphere* 93:2276–2283.

Cuevas E, Ausó E, Telefent M, Morreale de Escobar G, Sotelo C, and Berbel P (2005) Transient maternal hypothyroxinemia at onset of corticogenesis alters tangential migration of medial ganglionic eminence-derived neurons. *Eur J Neurosci* 22:541–551.

de Barros AL, Bae JH, Borges CS, Rosa JL, Cavariani MM, Silva PV, Pinheiro PFF, Anselmo-Franci JA, and Arena AC (2017) Perinatal exposure to insecticide fipronil: effects on the reproductive system in male rats. *Reprod Fertil Dev* 29:1130–1143.

de Barros AL, Rosa JL, Cavariani MM, Borges CS, Villela E, Silva P, Bae JH, Anselmo-Franci JA, and Cristina Arena A (2016) In utero and lactational exposure to fipronil in female rats: pregnancy outcomes and sexual development. *J Toxicol Environ Health A* 79:266–273.

Dickinson RG, Fowler DW, and Kluck RM (1989) Maternofetal transfer of phenytoin, p-hydroxyphenytoin and p-hydroxyphenytoin-glucuronide in the perfused human placenta. *Clin Exp Pharmacol Physiol* 16:789–797.

European Food Safety Authority (EFSA) (2006) Conclusion regarding the peer review of the pesticide risk assessment of the active substance fipronil. *EFSA J* 4:65r.

Griffiths SK and Campbell JP (2014) Placental structure, function and drug transfer. *Cont Educ Anaesth Crit Care Pain* 15:84–89.

Hainzl D, Cole LM, and Casida JE (1998) Mechanisms for selective toxicity of fipronil insecticide and its sulfone metabolite and desulfinyl photoproduct. *Chem Res Toxicol* 11:1529–1535.

Hakkola J, Pasanen M, Hukkanen J, Pelkonen O, Mäenpää J, Edwards RJ, Boobis AR, and Raunio H (1996) Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. *Biochem Pharmacol* 51:403–411.

Hakkola J, Pelkonen O, Pasanen M, and Raunio H (1998) Xenobiotic-metabolizing cytochrome P450 enzymes in the human fetoplacental unit: role in intrauterine toxicity. *Crit Rev Toxicol* 28:35–72.

Han LW, Gao C, and Mao Q (2018) An update on expression and function of P-gp/ABCB1 and BCRP/ABCG2 in the placenta and fetus. *Expert Opin Drug Metab Toxicol* 14:817–829.

Herin F, Boutet-Robinet E, Levant A, Dularent S, Manika M, Galaty-Bouju F, Caron P, and Soulat J-M (2011) Thyroid function tests in persons with occupational exposure to fipronil. *Thyroid* 21:701–706.

Hines RN (2008) The ontogeny of drug metabolism enzymes and implications for adverse drug events. *Pharmacol Ther* 118:250–267.

Horozok L, Raymond V, Sattelle DB, and Wolstenholme AJ (2001) GLC-3: a novel fipronil and BIDN-sensitive, but picrotoxinin-insensitive, L-glutamate-gated chloride channel subunit from *Caenorhabditis elegans*. *Br J Pharmacol* 132:1247–1254.

JMPR (1997) Pesticide Residues in Food, 1997: Report of the Joint Meeting of the FAO Panel of Experts on Pesticide Residues in Food and the Environment and the WHO Core Assessment Group on Pesticide Residues, 1997 22 Sept–1 Oct. Food and Agriculture Organization of the United Nations, Lyons, France.

Kim YA, Yoon YS, Kim HS, Jeon SJ, Cole E, Lee J, Kho Y, and Cho YH (2019) Distribution of fipronil in humans, and adverse health outcomes of in utero fipronil sulfone exposure in newborns. *Int J Hyg Environ Health* 222:524–532.

Lee SJ, Mulay P, Diebolt-Brown B, Lackovic MJ, Mehler LN, Beckman J, Waltz J, Prado JB, Mitchell YA, Higgins SA, et al. (2010) Acute illnesses associated with exposure to fipronil—surveillance data from 11 states in the United States, 2001–2007. *Clin Toxicol (Phila)* 48:737–744.

Leghait J, Gayraud V, Picard-Hagen N, Camp M, Perdu E, Toutain P-L, and Vigié C (2009) Fipronil-induced disruption of thyroid function in rats is mediated by increased total and free thyroxine clearances concomitantly to increased activity of hepatic enzymes. *Toxicology* 255:38–44.

Lin CC, Yen JC, Wu YT, Lin LC, and Tsai TH (2012) Chemical analysis and transplacental transfer of oseltamivir and oseltamivir carboxylic acid in pregnant rats. *PLoS One* 7:e46062.

Ma WL, Gao C, Bell EM, Druschel CM, Caggana M, Aldous KM, Louis GM, and Kannan K (2014) Analysis of polychlorinated biphenyls and organochlorine pesticides in archived dried blood spots and its application to track temporal trends of environmental chemicals in newborns. *Environ Res* 133:204–210.

Mohamed F, Senarathna L, Percy A, Abeyewardene M, Eaglesham G, Cheng R, Azher S, Hittarage A, Dissanayake W, Sheriff MH, et al. (2004) Acute human self-poisoning with the N-phenylpyrazole insecticide fipronil—a GABAA-gated chloride channel blocker. *J Toxicol Clin Toxicol* 42:955–963.

Pérez R, Palma C, Núñez MJ, and Cox J (2008) Pharmacokinetics of ivermectin after maternal or fetal intravenous administration in sheep. *J Vet Pharmacol Ther* 31:406–414.

Qi W, Ma X, He W, Chen W, Zou M, Gurr GM, Vasseur L, and You M (2016) Characterization and expression profiling of ATP-binding cassette transporter genes in the diamondback moth, *Plutella xylostella* (L.). *BMC Genomics* 17:760.

Roques BB, Lacroix MZ, Puel S, Gayraud V, Picard-Hagen N, Jouanin I, Perdu E, Martin PG, and Vigié C (2012) CYP450-dependent biotransformation of the insecticide fipronil into fipronil sulfone can mediate fipronil-induced thyroid disruption in rats [published correction appears in *Toxicol Sci* (2012) 130:444–445]. *Toxicol Sci* 127:29–41.

Sala M, Ribas-Fitó N, Cardo E, de Muga ME, Marco E, Mazón C, Verdú A, Grimalt JO, and Sunyer J (2001) Levels of hexachlorobenzene and other organochlorine compounds in cord blood: exposure across placenta. *Chemosphere* 43:895–901.

Sastry BV (1999) Techniques to study human placental transport. *Adv Drug Deliv Rev* 38:17–39.

Scharf ME, Siegfried BD, Meinke LJ, and Chandler LD (2000) Fipronil metabolism, oxidative sulfone formation and toxicity among organophosphate- and carbamate-resistant and susceptible western corn rootworm populations. *Pest Manag Sci* 56:757–766.

Stafford EG, Tell LA, Lin Z, Davis JL, Vickroy TW, Riviere JE, and Baynes RE (2018) Consequences of fipronil exposure in egg-laying hens. *J Am Vet Med Assoc* 253:57–60.

Stehr CM, Linbo TL, Incardona JP, and Scholz NL (2006) The developmental neurotoxicity of fipronil: notochord degeneration and locomotor defects in zebrafish embryos and larvae. *Toxicol Sci* 92:270–278.

Syme MR, Paxton JW, and Keelan JA (2004) Drug transfer and metabolism by the human placenta. *Clin Pharmacokinet* 43:487–514.

Tang J, Amin Usmani K, Hodgson E, and Rose RL (2004) In vitro metabolism of fipronil by human and rat cytochrome P450 and its interactions with testosterone and diazepam. *Chem Biol Interact* 147:319–329.

- Tingle CC, Rother JA, Dewhurst CF, Lauer S, and King WJ (2003) Fipronil: environmental fate, ecotoxicology, and human health concerns. *Rev Environ Contam Toxicol* **176**:1–66.
- Udo MS, Sandini TM, Reis TM, Bernardi MM, and Spinosa HS (2014) Prenatal exposure to a low fipronil dose disturbs maternal behavior and reflex development in rats. *Neurotoxicol Teratol* **45**: 27–33.
- Wagner SD, Kurobe T, Hammock BG, Lam CH, Wu G, Vasylieva N, Gee SJ, Hammock BD, and Teh SJ (2017) Developmental effects of fipronil on Japanese Medaka (*Oryzias latipes*) embryos. *Chemosphere* **166**:511–520.
- Zhang X, Wu X, Lei B, Jing Y, Jiang Z, Zhang X, Fang X, and Yu Y (2018) Transplacental transfer characteristics of organochlorine pesticides in paired maternal and cord sera, and placentas and possible influencing factors. *Environ Pollut* **233**:446–454.
- Zhao X, Yeh JZ, Salgado VL, and Narahashi T (2005) Sulfone metabolite of fipronil blocks gamma-aminobutyric acid- and glutamate-activated chloride channels in mammalian and insect neurons. *J Pharmacol Exp Ther* **314**:363–373.
- Zoeller RT and Rovet J (2004) Timing of thyroid hormone action in the developing brain: clinical observations and experimental findings. *J Neuroendocrinol* **16**:809–818.

Address correspondence to: Tung-Hu Tsai, Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, No. 155, Li-Nong Street Section 2, Taipei 112, Taiwan. E-mail: thtsai@ym.edu.tw
